

Updated guidelines for using Interferon Gamma Release tuberculosis infection - United States, 2010

MMWR Recommendations and Reports

59, 1-25

Citation Report

#	ARTICLE	IF	CITATIONS
1	Hard to Conceive. <i>New England Journal of Medicine</i> , 2010, 363, 965-970.	13.9	7
2	Cost Effectiveness of Interferon-Gamma Release Assay for Tuberculosis Screening of Rheumatoid Arthritis Patients prior to Initiation of Tumor Necrosis Factor- α Antagonist Therapy. <i>Molecular Diagnosis and Therapy</i> , 2010, 14, 367-373.	1.6	28
3	Etiology and management of genitourinary tuberculosis. <i>Nature Reviews Urology</i> , 2011, 8, 678-688.	1.9	99
4	Current Concepts in the Management of Tuberculosis. <i>Mayo Clinic Proceedings</i> , 2011, 86, 348-361.	1.4	151
5	Role of the Clinical Mycobacteriology Laboratory in Diagnosis and Management of Tuberculosis in Low-Prevalence Settings. <i>Journal of Clinical Microbiology</i> , 2011, 49, 772-776.	1.8	48
6	Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 435-444.	4.6	187
7	Enhanced tuberculosis case detection among substitution treatment patients: a randomized controlled trial. <i>BMC Research Notes</i> , 2011, 4, 192.	0.6	7
8	Outbreak of Tuberculosis among Guatemalan Immigrants in Rural Minnesota, 2008. <i>Public Health Reports</i> , 2011, 126, 726-732.	1.3	6
9	Tuberculosis among Foreign-born Persons, Singapore, 2000-2009. <i>Emerging Infectious Diseases</i> , 2011, 17, 517-519.	2.0	10
10	Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents. <i>Annals of Laboratory Medicine</i> , 2011, 31, 271-278.	1.2	31
11	Analysis of Factors Lowering Sensitivity of Interferon- γ Release Assay for Tuberculosis. <i>PLoS ONE</i> , 2011, 6, e23806.	1.1	58
12	Longitudinal Analysis of QuantiFERON-TB Gold In-Tube in Children with Adult Household Tuberculosis Contact in South Africa: A Prospective Cohort Study. <i>PLoS ONE</i> , 2011, 6, e26787.	1.1	25
13	Interferon-Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 230-238.	0.9	260
14	Interferon Gamma Release Assay Compared With the Tuberculin Skin Test for Latent Tuberculosis Detection in Pregnancy. <i>Obstetrics and Gynecology</i> , 2011, 118, 1363-1370.	1.2	23
17	Performance of tuberculin skin test and interferon gamma assay for the diagnosis of latent tuberculosis infection in juvenile idiopathic arthritis. <i>Clinical Rheumatology</i> , 2011, 30, 1189-1193.	1.0	19
19	Improving the Diagnosis of Tuberculosis: From QuantiFERON to New Techniques to Diagnose Tuberculosis Infections. <i>Current HIV/AIDS Reports</i> , 2011, 8, 153-163.	1.1	6
20	The Use of Interferon- γ Release Assays for Tuberculosis Screening in International Travelers. <i>Current Infectious Disease Reports</i> , 2011, 13, 229-235.	1.3	4
21	IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. <i>BMC Infectious Diseases</i> , 2011, 11, 135.	1.3	74

#	ARTICLE	IF	CITATIONS
22	Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB [®]) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. <i>BMC Infectious Diseases</i> , 2011, 11, 319.	1.3	28
23	Latent tuberculosis infection screening for laboratory personnel using interferon- γ release assay and tuberculin skin test in Korea: an intermediate incidence setting. <i>Journal of Clinical Laboratory Analysis</i> , 2011, 25, 382-388.	0.9	11
24	Priorities for Screening and Treatment of Latent Tuberculosis Infection in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 590-601.	2.5	139
25	Novel Developments in the Epidemic of Human Immunodeficiency Virus and Tuberculosis Coinfection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 987-997.	2.5	29
26	Within-Subject Variability of Mycobacterium tuberculosis-Specific Gamma Interferon Responses in German Health Care Workers. <i>Vaccine Journal</i> , 2011, 18, 1176-1182.	3.2	65
27	Point-Counterpoint: Should Interferon Gamma Release Assays Become the Standard Method for Screening Patients for Mycobacterium tuberculosis Infections in the United States?. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2086-2092.	1.8	10
28	Comparison of Two Gamma Interferon Release Assays and Tuberculin Skin Testing for Tuberculosis Screening in a Cohort of Patients with Rheumatic Diseases Starting Anti-Tumor Necrosis Factor Therapy. <i>Vaccine Journal</i> , 2011, 18, 2102-2108.	3.2	57
29	Impact of Targeted Testing for Latent Tuberculosis Infection Using Commercially Available Diagnostics. <i>Clinical Infectious Diseases</i> , 2011, 53, 234-244.	2.9	14
30	Preanalytical Delay Reduces Sensitivity of QuantiFERON-TB Gold In-Tube Assay for Detection of Latent Tuberculosis Infection. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3061-3064.	1.8	55
31	Are interferon- γ release assays useful for diagnosing active tuberculosis in a high-burden setting?. <i>European Respiratory Journal</i> , 2011, 38, 649-656.	3.1	71
32	Interferon- γ Release Assays for Active Pulmonary Tuberculosis Diagnosis in Adults in Low- and Middle-Income Countries: Systematic Review and Meta-analysis. <i>Journal of Infectious Diseases</i> , 2011, 204, S1120-S1129.	1.9	241
33	HIV and Tuberculosis: a Deadly Human Syndemic. <i>Clinical Microbiology Reviews</i> , 2011, 24, 351-376.	5.7	562
34	Psoriatic Disease and Tuberculosis Nowadays. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-10.	3.3	16
35	Delineating a Retesting Zone Using Receiver Operating Characteristic Analysis on Serial QuantiFERON Tuberculosis Test Results in US Healthcare Workers. <i>Pulmonary Medicine</i> , 2012, 2012, 1-7.	0.5	34
36	Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. <i>European Respiratory Journal</i> , 2012, 39, 163-171.	3.1	26
37	Tuberculosis in Pregnant and Postpartum Women: Epidemiology, Management, and Research Gaps. <i>Clinical Infectious Diseases</i> , 2012, 55, 1532-1549.	2.9	227
38	Multicytokine Detection Improves Latent Tuberculosis Diagnosis in Health Care Workers. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1711-1717.	1.8	27
39	Dysfunction of Natural Killer T Cells in Patients with Active Mycobacterium tuberculosis Infection. <i>Infection and Immunity</i> , 2012, 80, 2100-2108.	1.0	77

#	ARTICLE	IF	CITATIONS
40	Outbreak of Transient Conversions of the QuantiFERON-TB Gold In-Tube Test in Laboratory Health Care Worker Screenings. <i>Vaccine Journal</i> , 2012, 19, 954-960.	3.2	4
41	Can Social History Variables Predict Prison Inmates' Risk for Latent Tuberculosis Infection?. <i>Tuberculosis Research and Treatment</i> , 2012, 2012, 1-7.	0.2	4
42	Immunosuppression Adversely Affects TST but Not IGRAs in Patients with Psoriasis or Inflammatory Musculoskeletal Diseases. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-8.	0.9	17
43	The Use of Interferon Gamma Release Assays in the Diagnosis of Active Tuberculosis. <i>Tuberculosis Research and Treatment</i> , 2012, 2012, 1-4.	0.2	8
44	Maintenance of Sensitivity of the T-SPOT. TB Assay after Overnight Storage of Blood Samples, Dar es Salaam, Tanzania. <i>Tuberculosis Research and Treatment</i> , 2012, 2012, 1-4.	0.2	4
45	Discordance among Commercially Available Diagnostics for Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 427-434.	2.5	52
46	Rapid diagnosis of <i>Mycobacterium tuberculosis</i> infection in children using interferon-gamma release assays (IGRAs). <i>Allergy and Asthma Proceedings</i> , 2012, 33, 217-226.	1.0	12
47	Clinical spectrum of tuberculous optic neuropathy. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2012, 2, 183-189.	1.2	47
48	Is It Time to Replace the Tuberculin Skin Test With a Blood Test?. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 241.	3.8	22
49	Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. <i>Infection</i> , 2012, 40, 431-435.	2.3	31
50	Serial interferon- γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. <i>Clinical Rheumatology</i> , 2012, 31, 1567-1575.	1.0	29
51	Distinct Effector Memory CD4+ T Cell Signatures in Latent <i>Mycobacterium tuberculosis</i> Infection, BCG Vaccination and Clinically Resolved Tuberculosis. <i>PLoS ONE</i> , 2012, 7, e36046.	1.1	75
52	In routine UK hospital practice T-SPOT.TB is useful in some patients with a modest pre-test probability of active tuberculosis. <i>European Journal of Internal Medicine</i> , 2012, 23, 363-367.	1.0	6
53	Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2012, 12, 107.	1.3	26
54	Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. <i>BMC Infectious Diseases</i> , 2012, 12, 169.	1.3	46
55	QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis. <i>BMC Infectious Diseases</i> , 2012, 12, 360.	1.3	14
56	Negative effect of smoking on the performance of the QuantiFERON TB gold in tube test. <i>BMC Infectious Diseases</i> , 2012, 12, 379.	1.3	23
57	Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review. <i>Journal of Occupational Medicine and Toxicology</i> , 2012, 7, 6.	0.9	73

#	ARTICLE	IF	CITATIONS
58	Current Approaches to Tuberculosis in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 283-9.	3.8	18
59	Programmatic Impact of QuantiFERON-TB Gold In-Tube Implementation on Latent Tuberculosis Diagnosis and Treatment in a Public Health Clinic. <i>PLoS ONE</i> , 2012, 7, e36551.	1.1	28
60	QuantiFERON®-TB Gold In-Tube Performance for Diagnosing Active Tuberculosis in Children and Adults in a High Burden Setting. <i>PLoS ONE</i> , 2012, 7, e37851.	1.1	42
61	Bronchoalveolar Lavage Enzyme-Linked Immunospot for Diagnosis of Smear-Negative Tuberculosis in HIV-Infected Patients. <i>PLoS ONE</i> , 2012, 7, e39838.	1.1	17
62	Within-Subject Interlaboratory Variability of QuantiFERON-TB Gold In-Tube Tests. <i>PLoS ONE</i> , 2012, 7, e43790.	1.1	38
63	Potential Role of <i>M. tuberculosis</i> Specific IFN- γ and IL-2 ELISPOT Assays in Discriminating Children with Active or Latent Tuberculosis. <i>PLoS ONE</i> , 2012, 7, e46041.	1.1	58
64	Determining Mycobacterium tuberculosis Infection among BCG-Immunised Ugandan Children by T-SPOT.TB and Tuberculin Skin Testing. <i>PLoS ONE</i> , 2012, 7, e47340.	1.1	30
65	Factors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis. <i>Tuberculosis and Respiratory Diseases</i> , 2012, 72, 416.	0.7	38
66	An Eight-Month-Old Child with Cervical Adenitis. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2012, 23, e53-e54.	0.7	0
67	Interferon-Gamma Release Assays for Screening of Health Care Workers in Low Tuberculosis Incidence Settings: Dynamic Patterns and Interpretational Challenges. <i>Canadian Respiratory Journal</i> , 2012, 19, 81-83.	0.8	21
68	Application and Interpretation of an Interferon-Gamma Release Assay: Results of an Audit in a Canadian Centre. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2012, 23, 183-186.	0.7	0
69	Use of Interferon-Gamma Release Assays in a Health Care Worker Screening Program: Experience from a Tertiary Care Centre in the United States. <i>Canadian Respiratory Journal</i> , 2012, 19, 84-88.	0.8	34
70	Crohn's disease or TB - the perennial question and diagnostic pitfalls. <i>BMJ Case Reports</i> , 2012, 2012, bcr0120125620-bcr0120125620.	0.2	2
71	Current management options for latent tuberculosis: a review. <i>Infection and Drug Resistance</i> , 2012, 5, 163.	1.1	19
72	Recent advances in the diagnosis of Mycobacterium tuberculosis. <i>Germes</i> , 2012, 2, 110-120.	0.5	12
73	Multistate Outbreak of MDR TB Identified by Genotype Cluster Investigation. <i>Emerging Infectious Diseases</i> , 2012, 18, 113-116.	2.0	13
74	Gastrointestinal Cancer Educational Case Series: A 65 year-old Female with Locally Advanced Gastric Cancer and a Supraclavicular Lymph Node. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 93-96.	0.6	1
75	Latent tuberculosis infection in children: diagnostic approaches. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 1285-1294.	1.3	18

#	ARTICLE	IF	CITATIONS
76	Quality Improvement of Tuberculosis Screening in Foreign-Born Patients. <i>Journal of Immigrant and Minority Health</i> , 2012, 14, 1-5.	0.8	4
77	Screening for tuberculosis and the use of a borderline zone for the interpretation of the interferon- γ release assay (IGRA) in Portuguese healthcare workers. <i>Journal of Occupational Medicine and Toxicology</i> , 2013, 8, 1.	0.9	28
78	Implementation of an Interferon-Gamma Release Assay to Screen for Tuberculosis in Refugees and Immigrants. <i>Journal of Immigrant and Minority Health</i> , 2013, 15, 686-692.	0.8	6
79	Cost-Effectiveness of Latent Tuberculosis Screening Before Steroid Therapy for Idiopathic Nephrotic Syndrome in Children. <i>American Journal of Kidney Diseases</i> , 2013, 61, 22-32.	2.1	17
80	Screening for latent tuberculosis in Norwegian health care workers: high frequency of discordant tuberculin skin test positive and interferon-gamma release assay negative results. <i>BMC Public Health</i> , 2013, 13, 353.	1.2	20
81	Status and Current Role of "Interferon Gamma Release Assays" vs. "Tuberculin Skin Testing" in Diagnosis of Tubercular Disease. <i>Indian Journal of Pediatrics</i> , 2013, 80, 334-336.	0.3	1
82	Risk factors for false-negative results of T-SPOT.TB and tuberculin skin test in extrapulmonary tuberculosis. <i>Infection</i> , 2013, 41, 1089-1095.	2.3	35
83	Serpiginous Choroiditis and Infectious Multifocal Serpiginoid Choroiditis. <i>Survey of Ophthalmology</i> , 2013, 58, 203-232.	1.7	179
84	An Update on Granulomatous Diseases of the Oral Tissues. <i>Dental Clinics of North America</i> , 2013, 57, 657-671.	0.8	24
85	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. <i>Arthritis and Rheumatism</i> , 2013, 65, 2499-2512.	6.7	211
86	Challenges with QuantiFERON-TB Gold Assay for Large-Scale, Routine Screening of U.S. Healthcare Workers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1005-1010.	2.5	89
87	Impact of Blood Volume, Tube Shaking, and Incubation Time on Reproducibility of QuantiFERON-TB Gold In-Tube Assay. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3521-3526.	1.8	47
88	Diagnosis and treatment of latent tuberculosis infection: an update. <i>Current Respiratory Care Reports</i> , 2013, 2, 199-207.	0.6	17
89	Challenging Issues in Tuberculosis in Solid Organ Transplantation. <i>Clinical Infectious Diseases</i> , 2013, 57, 1473-1482.	2.9	60
90	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. <i>Arthritis Care and Research</i> , 2013, 65, 1551-1563.	1.5	211
91	Comparison of two interferon-gamma release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB) in testing for latent tuberculosis infection among HIV-infected adults. <i>International Journal of STD and AIDS</i> , 2013, 24, 775-779.	0.5	17
92	Diagnostic techniques for inflammatory eye disease: past, present and future: a review. <i>BMC Ophthalmology</i> , 2013, 13, 41.	0.6	4
93	Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases. <i>Clinical and Experimental Medicine</i> , 2013, 13, 177-186.	1.9	27

#	ARTICLE	IF	CITATIONS
94	Cytotoxic response persists in subjects treated for tuberculosis decades ago. BMC Infectious Diseases, 2013, 13, 573.	1.3	2
95	Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of Georgia. BMC Infectious Diseases, 2013, 13, 513.	1.3	24
96	How should I interpret an interferon gamma release assay result for tuberculosis infection?: Table 1. Thorax, 2013, 68, 298-301.	2.7	31
97	Trajectories of tuberculosis-specific interferon-gamma release assay responses among medical and nursing students in rural India. Journal of Epidemiology and Global Health, 2013, 3, 105.	1.1	14
98	Conversion rates of an interferon- γ release assay and the tuberculin skin test in the serial monitoring of healthcare workers. Infection, 2013, 41, 511-516.	2.3	9
99	Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 206-211.	2.5	155
100	Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nature Reviews Rheumatology, 2013, 9, 524-531.	3.5	49
101	Prevention of infection caused by immunosuppressive drugs in gastroenterology. Therapeutic Advances in Chronic Disease, 2013, 4, 167-185.	1.1	72
102	Laboratory support in the diagnosis of uveitis. Indian Journal of Ophthalmology, 2013, 61, 269.	0.5	24
103	Interferon-gamma treatment kinetics among patients with active pulmonary tuberculosis. Nigerian Medical Journal, 2013, 54, 376.	0.6	3
104	Prevalence of Latent and Active Tuberculosis among Dairy Farm Workers Exposed to Cattle Infected by Mycobacterium bovis. PLoS Neglected Tropical Diseases, 2013, 7, e2177.	1.3	57
105	Cost-effectiveness of QuantiFERON Testing Before Initiation of Biological Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 2444-2449.	0.9	10
106	Long-Term Immune Responses to Coxiella burnetii after Vaccination. Vaccine Journal, 2013, 20, 129-133.	3.2	31
107	Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Pediatric Infectious Disease Journal, 2013, 32, i.	1.1	46
108	Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence. Pulmonary Medicine, 2013, 2013, 1-11.	0.5	107
110	Prevalence of latent tuberculosis infection and risk of infection in patients with chronic kidney disease undergoing hemodialysis in a referral center in Brazil. Jornal Brasileiro De Pneumologia, 2013, 39, 214-220.	0.4	4
111	Immunologic Diagnosis of Active Tuberculosis. Infection and Chemotherapy, 2013, 45, 110.	1.0	0
112	Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma. Blood Research, 2013, 48, 35.	0.5	12

#	ARTICLE	IF	CITATIONS
113	Prevalence and Incidence of Latent Tuberculosis Infection in Georgian Healthcare Workers. PLoS ONE, 2013, 8, e58202.	1.1	45
114	Tuberculosis Screening by Tuberculosis Skin Test or QuantiFERON®-TB Gold In-Tube Assay among an Immigrant Population with a High Prevalence of Tuberculosis and BCG Vaccination. PLoS ONE, 2013, 8, e82727.	1.1	23
115	Indeterminate T-SPOT.<i>TB</i> Test Results in Patients with Suspected Extrapulmonary Tuberculosis in Routine Clinical Practice. Infection and Chemotherapy, 2013, 45, 44.	1.0	21
116	Immune Response to Mycobacterial Infection: Lessons from Flow Cytometry. Clinical and Developmental Immunology, 2013, 2013, 1-9.	3.3	7
117	Safe Re-administration of Tumor Necrosis Factor-alpha (TNF α) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNF α Therapy. Journal of Korean Medical Science, 2014, 29, 38.	1.1	13
118	The Association between Active and Passive Smoking and Latent Tuberculosis Infection in Adults and Children in the United States: Results from NHANES. PLoS ONE, 2014, 9, e93137.	1.1	29
119	Opportunities for Tuberculosis Diagnosis and Prevention among Persons Living with HIV: A Cross-Sectional Study of Policies and Practices at Four Large Ryan White Program-Funded HIV Clinics. PLoS ONE, 2014, 9, e101313.	1.1	6
120	Integrated Screening for Tuberculosis and HIV in Tuberculosis Contact Investigations: Lessons Learned in North Carolina. Public Health Reports, 2014, 129, 21-25.	1.3	4
121	Serial QuantiFERON-TB Gold In-Tube assay and tuberculin skin test to diagnose latent tuberculosis in household Mexican contacts: conversion and reversion rates and associated factors using conventional and borderline zone definitions. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 863-870.	0.8	6
122	Follow-up Testing of Interferon-Gamma Release Assays Are Useful in Ankylosing Spondylitis Patients Receiving Anti-Tumor Necrosis Factor Alpha for Latent Tuberculosis Infection. Journal of Korean Medical Science, 2014, 29, 1090.	1.1	11
123	Factors Associated with a Strong Response to the T-SPOT.<i>TB</i> in Patients with Extrapulmonary Tuberculosis. Infection and Chemotherapy, 2014, 46, 248.	1.0	10
124	Interferon- γ Enzyme-Linked Immunospot Assay in Patients with Tuberculosis and Healthy Adults. Tuberculosis and Respiratory Diseases, 2014, 76, 23.	0.7	6
125	The Usefulness of Interferon-gamma Release Assay for Diagnosis of Tuberculosis-related Uveitis in Korea. Korean Journal of Ophthalmology: KJO, 2014, 28, 226.	0.5	16
126	HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2Åyear follow-up; a Norwegian prospective multicenter study. BMC Infectious Diseases, 2014, 14, 667.	1.3	19
127	Quantiferon Gold-in-tube assay for TB screening in HIV infected children: influence of quantitative values. BMC Infectious Diseases, 2014, 14, 516.	1.3	10
128	Risk factors for latent tuberculosis infection in close contacts of active tuberculosis patients in South Korea: a prospective cohort study. BMC Infectious Diseases, 2014, 14, 566.	1.3	29
129	Efficacy and safety of pateclizumab (anti-lymphotoxin- α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Research and Therapy, 2014, 16, 467.	1.6	38
130	Concordant or discordant results by the tuberculin skin test and the quantiFERON-TB test in children reflect immune biomarker profiles. Genes and Immunity, 2014, 15, 265-274.	2.2	8

#	ARTICLE	IF	CITATIONS
131	The Usefulness of the Tuberculosis Skin Test and the Interferon-gamma Release Assay in the Diagnosis of Latent Tuberculosis Infection in South Korea. <i>Osong Public Health and Research Perspectives</i> , 2014, 5, S18-S23.	0.7	3
132	High Proportion of Indeterminate QuantiFERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu088.	0.4	18
133	Update on cutaneous tuberculosis. <i>Anais Brasileiros De Dermatologia</i> , 2014, 89, 925-938.	0.5	61
134	Decline in Tuberculosis among Mexico-Born Persons in the United States, 2000–2010. <i>Annals of the American Thoracic Society</i> , 2014, 11, 480-488.	1.5	8
135	Estimated Prevalence of Tuberculosis Infection Among a New York City Clinic Population Using Interferon-gamma Release Assays. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu047.	0.4	11
136	Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries. <i>Current Opinion in Pediatrics</i> , 2014, 26, 106-113.	1.0	21
137	Long-Incubation-Time Gamma Interferon Release Assays in Response to Purified Protein Derivative, ESAT-6, and/or CFP-10 for the Diagnosis of Mycobacterium tuberculosis Infection in Children. <i>Vaccine Journal</i> , 2014, 21, 111-118.	3.2	14
138	Interferon- γ Release Assays for the Evaluation of Tuberculosis Infection. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1460.	3.8	12
139	Tuberculin Skin Tests versus Interferon-Gamma Release Assays in Tuberculosis Screening among Immigrant Visa Applicants. <i>Tuberculosis Research and Treatment</i> , 2014, 2014, 1-11.	0.2	4
140	Added Value of QuantiFERON TB-Gold in-Tube for Detecting Latent Tuberculosis Infection among Persons Living with HIV/AIDS. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	8
141	Key Role of Effector Memory CD4+T Lymphocytes in a Short-Incubation Heparin-Binding Hemagglutinin Gamma Interferon Release Assay for the Detection of Latent Tuberculosis. <i>Vaccine Journal</i> , 2014, 21, 321-328.	3.2	28
142	Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a 2013 update. <i>BMC Infectious Diseases</i> , 2014, 14, S6.	1.3	114
143	Tuberculosis in childhood: a systematic review of national and international guidelines. <i>BMC Infectious Diseases</i> , 2014, 14, S3.	1.3	37
144	A Missed Tuberculosis Diagnosis Resulting in Hospital Transmission. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 534-537.	1.0	9
145	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. <i>Clinical Microbiology Reviews</i> , 2014, 27, 3-20.	5.7	662
146	Whole blood assay and visceral leishmaniasis: Challenges and promises. <i>Immunobiology</i> , 2014, 219, 323-328.	0.8	21
147	Tuberculosis in Children. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a017855-a017855.	2.9	66
148	Reproducibility of Interferon Gamma (IFN- γ) Release Assays. A Systematic Review. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1267-1276.	1.5	85

#	ARTICLE	IF	CITATIONS
149	Childhood tuberculosis: a concern of the modern world. <i>European Respiratory Review</i> , 2014, 23, 278-291.	3.0	28
150	A child presenting with tuberculous spondylitis in a single third cervical vertebra: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 284.	0.4	1
151	Update on Opportunistic Infections in the Era of Effective Antiretroviral Therapy. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 501-518.	1.9	27
152	Sarcoidosis vs. Sarcoid-like reactions: The Two Sides of the same Coin?. <i>Wiener Medizinische Wochenschrift</i> , 2014, 164, 247-259.	0.5	53
153	The Seasonality of Tuberculosis, Sunlight, Vitamin D, and Household Crowding. <i>Journal of Infectious Diseases</i> , 2014, 210, 774-783.	1.9	77
154	Prevalence and Treatment of Latent Tuberculosis Infection Among Newly Arrived Refugees in San Diego County, January 2010–October 2012. <i>American Journal of Public Health</i> , 2014, 104, e95-e102.	1.5	28
155	Effect of Isoniazid Therapy for Latent TB Infection on QuantiFERON-TB Gold In-Tube Responses in Adults With Positive Tuberculin Skin Test Results in a High TB Incidence Area. <i>Chest</i> , 2014, 145, 612-617.	0.4	37
156	A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program. <i>BMC Public Health</i> , 2015, 15, 1201.	1.2	13
157	The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor- α Blockers. <i>Journal of Korean Medical Science</i> , 2015, 30, 173.	1.1	28
158	Transnational Record Linkage for Tuberculosis Surveillance and Program Evaluation. <i>Public Health Reports</i> , 2015, 130, 475-484.	1.3	4
159	The Prevalence Rate of Tuberculin Skin Test Positive by Contacts Group to Predict the Development of Active Tuberculosis After School Outbreaks. <i>Tuberculosis and Respiratory Diseases</i> , 2015, 78, 349.	0.7	2
160	Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. <i>World Journal of Gastroenterology</i> , 2015, 21, 3308-3316.	1.4	64
161	Comparison of the Prevalence of Latent Tuberculosis Infection among Non-Dialysis Patients with Severe Chronic Kidney Disease, Patients Receiving Dialysis, and the Dialysis-Unit Staff: A Cross-Sectional Study. <i>PLoS ONE</i> , 2015, 10, e0124104.	1.1	22
162	Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot.TB Test. <i>PLoS ONE</i> , 2015, 10, e0125260.	1.1	6
163	Factors that Predict Negative Results of QuantiFERON-TB Gold In-Tube Test in Patients with Culture-Confirmed Tuberculosis: A Multicenter Retrospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0129792.	1.1	40
164	Enhanced Tuberculosis Infection Treatment Outcomes after Implementation of QuantiFERON [®] -Gold Testing. <i>PLoS ONE</i> , 2015, 10, e0138349.	1.1	8
165	The Significance of Sensitive Interferon Gamma Release Assays for Diagnosis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor- α Antagonist Therapy. <i>PLoS ONE</i> , 2015, 10, e0141033.	1.1	15
166	Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline - A longitudinal analysis after using TNF α blockers. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2015, 110, 921-928.	0.8	13

#	ARTICLE	IF	CITATIONS
167	Diagnosis and Treatment of Latent Tuberculosis Infection. <i>Tuberculosis and Respiratory Diseases</i> , 2015, 78, 56.	0.7	31
168	Screening Optimization of Latent Tuberculosis Infection in Rheumatoid Arthritis Patients. <i>Arthritis</i> , 2015, 2015, 1-8.	2.0	6
169	Incidence of occupational latent tuberculosis infection in South African healthcare workers. <i>European Respiratory Journal</i> , 2015, 45, 1364-1373.	3.1	41
170	A Workplace Tuberculosis Case Investigation in the Presence of Immigrant Contacts from High Prevalence Countries. <i>Journal of Community Health</i> , 2015, 40, 576-580.	1.9	6
171	In vitro immunomodulation for enhancing T cell-based diagnosis of Mycobacterium tuberculosis infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 41-45.	0.8	0
172	Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 605-617.	2.5	28
173	Gamma Interferon Assays Used in the Diagnosis of Tuberculosis. <i>Vaccine Journal</i> , 2015, 22, 845-849.	3.2	10
174	Challenges in Obtaining Estimates of the Risk of Tuberculosis Infection During Overseas Deployment. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 1172-1178.	0.6	3
175	General and advanced diagnostic tools to detect Mycobacterium tuberculosis and their drug susceptibility: a review. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 851-861.	1.3	20
176	Optimizing the Detection of Recent Tuberculosis Infection in Children in a High Tuberculosis HIV Burden Setting. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 820-830.	2.5	46
177	Identification of Mycobacterium tuberculosis PPE68-Specific HLA-A*0201-Restricted Epitopes for Tuberculosis Diagnosis. <i>Current Microbiology</i> , 2015, 70, 769-778.	1.0	8
178	Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON®-TB Gold In-tube. <i>BMC Infectious Diseases</i> , 2015, 15, 59.	1.3	16
179	Challenges in assessing transmission of Mycobacterium tuberculosis in long-term-care facilities. <i>American Journal of Infection Control</i> , 2015, 43, 992-996.	1.1	8
180	Effectiveness of contact investigations for tuberculosis control in Arkansas. <i>Journal of Theoretical Biology</i> , 2015, 380, 238-246.	0.8	12
181	The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. <i>RMD Open</i> , 2015, 1, e000044-e000044.	1.8	14
182	Missed Opportunities for Tuberculosis Screening in Primary Care. <i>Journal of Pediatrics</i> , 2015, 166, 1240-1245.e1.	0.9	9
183	Infection Prevention and the Medical Director. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 863-874.	2.2	8
184	Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening. <i>Tuberculosis</i> , 2015, 95, 275-287.	0.8	19

#	ARTICLE	IF	CITATIONS
185	Evaluation of QuantiFERON-TB Gold In-Tube and Tuberculin Skin Tests Among Immigrant Children Being Screened for Latent Tuberculosis Infection. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 35-39.	1.1	40
186	Host Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals. <i>EBioMedicine</i> , 2015, 2, 1160-1168.	2.7	50
187	Postexposure management of healthcare personnel to infectious diseases. <i>Hospital Practice (1995)</i> , 2015, 43, 107-127.	0.5	2
188	Risk factors for transmission of tuberculosis among United States-born African Americans and Whites. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1485-1492.	0.6	11
189	Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry. <i>Journal of Immunological Methods</i> , 2015, 417, 22-33.	0.6	68
190	Diagnosis of Latent Tuberculosis Infection with T-SPOT®.TB in a Predominantly Immigrant Population with Rheumatologic Disorders. <i>Lung</i> , 2015, 193, 3-11.	1.4	7
191	Screening of latent tuberculosis infection by interferon- γ release assays in rheumatic patients: a systemic review and meta-analysis. <i>Clinical Rheumatology</i> , 2016, 35, 417-425.	1.0	35
192	Renal Tuberculosis Presenting as a Mass Lesion in a Two-year-old Girl: Report of a rare case. <i>Sultan Qaboos University Medical Journal</i> , 2016, 16, e105-108.	0.3	6
193	Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT®.TB and QFT-GIT). <i>Journal of Thoracic Disease</i> , 2016, 8, 482-489.	0.6	3
194	Change in the Prevalence of Testing for Latent Tuberculosis Infection in the United States: 1999-2012. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-5.	0.8	4
195	A Perspective of the Diagnosis and Management of Congenital Tuberculosis. <i>Journal of Pathogens</i> , 2016, 2016, 1-8.	0.9	28
196	Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA. <i>BMC Infectious Diseases</i> , 2016, 16, 564.	1.3	18
197	Comparison of the Sensitivity of QuantiFERON-TB Gold In-Tube and T-SPOT.TB According to Patient Age. <i>PLoS ONE</i> , 2016, 11, e0156917.	1.1	37
198	Elevated Neopterin Levels Are Associated with Increased Tuberculosis Risk in Rheumatoid Arthritis Patients with QuantiFERON Conversion during Biologic Therapy. <i>PLoS ONE</i> , 2016, 11, e0166301.	1.1	6
199	Repeatability of QuantiFERON-TB Gold In-Tube Assay Results Near Cut-Off Points. <i>Annals of Laboratory Medicine</i> , 2016, 36, 76-78.	1.2	5
200	Health Profiles of Newly Arrived Refugee Children in the United States, 2006-2012. <i>American Journal of Public Health</i> , 2016, 106, 128-135.	1.5	50
201	<i>Mycobacterium Tuberculosis</i> Infection, Immigration Status, and Diagnostic Discordance: A Comparison of Tuberculin Skin Test and QuantiFERON®-TB Gold in-Tube Test among Immigrants to the U.S.. <i>Public Health Reports</i> , 2016, 131, 303-310.	1.3	11
202	Accuracy of the Bronchoalveolar Lavage Enzyme-Linked Immunospot Assay for the Diagnosis of Pulmonary Tuberculosis. <i>Medicine (United States)</i> , 2016, 95, e3183.	0.4	7

#	ARTICLE	IF	CITATIONS
203	Interferon-Gamma Release Assays and Pediatric Public Health Tuberculosis Screening: The San Francisco Program Experience 2005 to 2008. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2016, 5, 122-130.	0.6	23
204	Orbital and external ocular manifestations of <i>Mycobacterium tuberculosis</i> : A review of the literature. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2016, 4, 50-57.	0.6	15
205	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1579-1590.	1.5	43
206	IFN- γ Release Assay Result Is Associated with Disease Site and Death in Active Tuberculosis. <i>Annals of the American Thoracic Society</i> , 2016, 13, 2151-2158.	1.5	11
207	Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays. <i>BMC Public Health</i> , 2016, 16, 875.	1.2	11
208	Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. <i>Scientific Reports</i> , 2016, 6, 30781.	1.6	27
209	Inflammatory markers and clinical characteristics for predicting persistent positivity of interferon gamma release assay in dialysis population. <i>Scientific Reports</i> , 2016, 6, 34577.	1.6	6
210	Circulating granulysin levels in healthcare workers and latent tuberculosis infection estimated using interferon-gamma release assays. <i>BMC Infectious Diseases</i> , 2016, 16, 580.	1.3	7
211	Using IFN-gamma release assay to confirm tuberculin skin test improves the screening of latent tuberculosis infection in Italian healthcare workers. <i>Journal of Occupational Medicine and Toxicology</i> , 2016, 11, 29.	0.9	10
212	Utility of T-cell interferon- γ release assays for the diagnosis of female genital tuberculosis in a tertiary referral hospital in Beijing, China. <i>Medicine (United States)</i> , 2016, 95, e5200.	0.4	9
213	Effects of acute critical illnesses on the performance of interferon-gamma release assay. <i>Scientific Reports</i> , 2016, 6, 19972.	1.6	14
214	Potential role for interferon- γ release assays in tuberculosis screening in a remote Canadian community: a case series. <i>CMAJ Open</i> , 2016, 4, E535-E537.	1.1	1
215	Detection of latent tuberculosis infection among migrant farmworkers along the US-Mexico border. <i>BMC Infectious Diseases</i> , 2016, 16, 630.	1.3	15
216	Performance of interferon- γ release assays in the diagnosis of confirmed active tuberculosis in immunocompetent children: a new systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2016, 16, 131.	1.3	39
217	Isoniazid therapy for <i>Mycobacterium tuberculosis</i> infection in HIV clinics, Los Angeles, California. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 961-966.	0.6	4
218	Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population. <i>Clinical Rheumatology</i> , 2016, 35, 427-431.	1.0	11
219	Pulmonary responses to pathogen-specific antigens in latent <i>Mycobacterium tuberculosis</i> infection. <i>Tuberculosis</i> , 2016, 96, 158-164.	0.8	4
220	Latent Tuberculosis Infection Test Agreement in the National Health and Nutrition Examination Survey. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 493-500.	2.5	22

#	ARTICLE	IF	CITATIONS
221	Disseminated Tuberculosis in an Immunocompetent Patient: The Answer is in the Liver. GE Portuguese Journal of Gastroenterology, 2016, 23, 208-213.	0.3	13
222	Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay?. Journal of Dermatological Treatment, 2016, 27, 378-380.	1.1	8
223	Increased risk of latent tuberculous infection among persons with pre-diabetes and diabetes mellitus. International Journal of Tuberculosis and Lung Disease, 2016, 20, 71-78.	0.6	56
224	Comparing an Interferon Gamma Release Assay with the Tuberculin Skin Test During Pregnancy: Implications for Tuberculosis Screening During Prenatal Care. Maternal and Child Health Journal, 2016, 20, 1314-1320.	0.7	4
225	Latent Tuberculosis Infection Among Immigrant and Refugee Children Arriving in the United States: 2010. Journal of Immigrant and Minority Health, 2016, 18, 966-970.	0.8	25
226	Recommendations for the diagnosis of pediatric tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1-18.	1.3	29
227	Impact of Routine Quantiferon Testing on Latent Tuberculosis Diagnosis and Treatment in Refugees in Multnomah County, Oregon, November 2009â€“October 2012. Journal of Immigrant and Minority Health, 2016, 18, 292-300.	0.8	11
228	Prevalence of tuberculosis infection in healthcare workers of the public hospital network in MedellÃn, Colombia: a Bayesian approach. Epidemiology and Infection, 2017, 145, 1095-1106.	1.0	5
229	Intraocular manifestations of mycobacterium tuberculosis: A review of the literature. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2017, 7, 13-21.	0.6	35
230	Endocrine and Metabolic Aspects of Tuberculosis. Microbiology Spectrum, 2017, 5, .	1.2	22
231	Association of Body Mass Index with the Tuberculosis Infection: a Population-based Study among 17796 Adults in Rural China. Scientific Reports, 2017, 7, 41933.	1.6	31
232	Comparison of QuantiFERON-TB Gold In-Tube (QFT-GIT) and tuberculin skin test (TST) for diagnosis of latent tuberculosis in haemodialysis (HD) patients: a meta-analysis of estimates. Epidemiology and Infection, 2017, 145, 1824-1833.	1.0	10
233	Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infectious Diseases, The, 2017, 17, e327-e333.	4.6	87
234	Tuberculin skin test and interferon-gamma release assay use among privately insured persons in the United States. International Journal of Tuberculosis and Lung Disease, 2017, 21, 684-689.	0.6	4
235	Quantification of circulating <i>Mycobacterium tuberculosis</i> antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3969-3974.	3.3	93
236	A mode of error: Immunoglobulin binding protein (a subset of anti-citrullinated proteins) can cause false positive tuberculosis test results in rheumatoid arthritis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2017, 9, 5-9.	0.6	2
237	Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study. Clinical Infectious Diseases, 2017, 65, 2060-2068.	2.9	48
238	Tuberculosis Meningitis. Current Infectious Disease Reports, 2017, 19, 39.	1.3	34

#	ARTICLE	IF	CITATIONS
239	Severe Enteropathy and Hypogammaglobulinemia Complicating Refractory Mycobacterium tuberculosis Complex Disseminated Disease in a Child with IL-12R β 1 Deficiency. <i>Journal of Clinical Immunology</i> , 2017, 37, 732-738.	2.0	10
240	Infectious diseases prevalence, vaccination coverage, and diagnostic challenges in a population of internationally adopted children referred to a Tertiary Care Children's Hospital from 2009 to 2015. <i>Medicine (United States)</i> , 2017, 96, e6300.	0.4	20
241	Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of <i>Mycobacterium tuberculosis</i> Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 638-648.	2.5	124
242	CE. <i>American Journal of Nursing</i> , 2017, 117, 24-34.	0.2	4
243	Testing of tuberculosis infection among Chinese adolescents born after terminating the Bacillus Calmette-Guérin booster vaccination: subgroup analysis of a population-based cross-sectional study. <i>Frontiers of Medicine</i> , 2017, 11, 528-535.	1.5	12
244	QFT-Plus: a plus in variability? Evaluation of new generation IGRA in serial testing of students with a migration background in Germany. <i>Journal of Occupational Medicine and Toxicology</i> , 2017, 12, 1.	0.9	40
245	Tuberculous meningoencephalitis associated with brain tuberculomas during pregnancy: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 175.	0.4	7
246	Close contact interferon-gamma response to the new PstS1(285-374):CPF10: a preliminary 1-year follow-up study. <i>BMC Research Notes</i> , 2017, 10, 59.	0.6	6
247	Performance of QuantiFERON-TB Gold In-Tube assay in children receiving disease modifying anti-rheumatic drugs. <i>World Journal of Pediatrics</i> , 2017, 13, 472-478.	0.8	7
248	The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 457-461.	1.0	23
249	Diagnosis of tuberculous pleurisy with combination of adenosine deaminase and interferon- γ immunospot assay in a tuberculosis-endemic population. <i>Medicine (United States)</i> , 2017, 96, e8412.	0.4	15
250	Occupational Risk of Latent Tuberculosis Infection in Health Workers of 14 Military Hospitals. <i>Journal of Korean Medical Science</i> , 2017, 32, 1251.	1.1	11
251	Evaluation of a New IFN- γ Release Assay for Rapid Diagnosis of Active Tuberculosis in a High-Incidence Setting. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 117.	1.8	25
252	Tuberculosis Test Usage and Medical Expenditures from Outpatient Insurance Claims Data, 2013. <i>Tuberculosis Research and Treatment</i> , 2017, 2017, 1-9.	0.2	6
253	Assessment of the influence of direct tobacco smoke on infection and active TB management. <i>PLoS ONE</i> , 2017, 12, e0182998.	1.1	36
254	Host transcriptional responses following <i>ex vivo</i> re-challenge with <i>Mycobacterium tuberculosis</i> vary with disease status. <i>PLoS ONE</i> , 2017, 12, e0185640.	1.1	6
255	Assessment of the QuantiFERON-TB Gold In-Tube test for the detection of <i>Mycobacterium tuberculosis</i> infection in United States Navy recruits. <i>PLoS ONE</i> , 2017, 12, e0177752.	1.1	11
256	Decreased <i>ex vivo</i> production of interferon-gamma is associated with severity and poor prognosis in patients with lupus. <i>Arthritis Research and Therapy</i> , 2017, 19, 193.	1.6	14

#	ARTICLE	IF	CITATIONS
257	Risk factors for increased immune reconstitution in response to Mycobacterium tuberculosis antigens in tuberculosis HIV-infected, antiretroviral-naïve patients. BMC Infectious Diseases, 2017, 17, 606.	1.3	9
258	The Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers. Internal Medicine, 2017, 56, 773-779.	0.3	7
259	Prospective Comparison of QFT-GIT and T-SPOT.TB Assays for Diagnosis of Active Tuberculosis. Scientific Reports, 2018, 8, 5882.	1.6	31
260	Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis, 2018, 108, 201-210.	0.8	10
261	Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731775220.	0.5	11
262	Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria. Clinical Microbiology Reviews, 2018, 31, .	5.7	175
263	Potential Immunological Biomarkers for Detection of Mycobacterium tuberculosis Infection in a Setting Where M. tuberculosis Is Endemic, Ethiopia. Infection and Immunity, 2018, 86, .	1.0	12
264	Evaluation of risk factors for false-negative results with an antigen-specific peripheral blood-based quantitative T cell assay (T-SPOT [®] TB) in the diagnosis of active tuberculosis: A large-scale retrospective study in China. Journal of International Medical Research, 2018, 46, 1815-1825.	0.4	17
265	Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol. Clinical Rheumatology, 2018, 37, 2391-2397.	1.0	9
266	Medical management of drug-sensitive active thoracic tuberculosis: the work-up, radiographic findings and treatment. Journal of Thoracic Disease, 2018, 10, S3378-S3391.	0.6	4
267	Screening for Latent Tuberculosis Infection in Patients with Autoimmune Diseases Before Initiating TNF- and #945; Inhibitors Therapy. Materia Socio-medica, 2018, 30, 32.	0.3	0
268	Latent Tuberculosis Infection - Diagnosis and Treatment. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 651-655.	0.1	10
269	PPE17 (Rv1168c) protein of Mycobacterium tuberculosis detects individuals with latent TB infection. PLoS ONE, 2018, 13, e0207787.	1.1	23
270	Interferon- γ release assay as a sensitive diagnostic tool of latent tuberculosis infection in patients with HIV: a cross-sectional study. BMC Infectious Diseases, 2018, 18, 585.	1.3	19
271	Miliary tuberculosis presenting as a choroidal mass and a tuberculosis screening review. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2018, 13, 13-16.	0.6	1
272	Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection. Scientific Reports, 2018, 8, 15626.	1.6	23
273	Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru. PLoS ONE, 2018, 13, e0202191.	1.1	12
274	Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open, 2018, 8, e022445.	0.8	64

#	ARTICLE	IF	CITATIONS
275	Yield of testing and treatment for tuberculosis among foreign-born persons during contact investigations in the United States: A semi-systematic review. <i>PLoS ONE</i> , 2018, 13, e0200485.	1.1	2
276	Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent Tuberculosis Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy184.	0.4	18
277	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. <i>Intestinal Research</i> , 2018, 16, 4.	1.0	32
278	Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases. <i>Scientific Reports</i> , 2018, 8, 7881.	1.6	8
279	Using Reports of Latent Tuberculosis Infection Among Young Children to Identify Tuberculosis Transmission in New York City, 2006–2012. <i>American Journal of Epidemiology</i> , 2018, 187, 1303-1310.	1.6	1
280	Influence of Seasonality and Circulating Cytokines on Serial QuantiFERON Discordances. <i>Tuberculosis Research and Treatment</i> , 2018, 2018, 1-5.	0.2	5
281	Characteristics Associated with Negative Interferon- γ Release Assay Results in Culture-Confirmed Tuberculosis Patients, Texas, USA, 2013–2015. <i>Emerging Infectious Diseases</i> , 2018, 24, 534-540.	2.0	50
282	Severe BCG-osis Misdiagnosed as Multidrug-Resistant Tuberculosis in an IL-12 β -Deficient Peruvian Girl. <i>Journal of Clinical Immunology</i> , 2018, 38, 712-716.	2.0	8
283	Performance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic setting. <i>PLoS ONE</i> , 2018, 13, e0193589.	1.1	29
284	Management and diagnosis of tuberculosis in solid organ transplant candidates and recipients: Expert survey and updated review. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2018, 11, 37-46.	0.6	10
285	Functional and Phenotypic Changes of Natural Killer Cells in Whole Blood during Mycobacterium tuberculosis Infection and Disease. <i>Frontiers in Immunology</i> , 2018, 9, 257.	2.2	53
286	Evaluating latent tuberculosis infection diagnostics using latent class analysis. <i>Thorax</i> , 2018, 73, 1062-1070.	2.7	36
287	Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis. <i>PLoS ONE</i> , 2018, 13, e0197825.	1.1	22
288	Antigen 85B peptidomic analysis allows species-specific mycobacterial identification. <i>Clinical Proteomics</i> , 2018, 15, 1.	1.1	20
289	Modeling Diversity: Do Homogeneous Laboratory Strains Limit Discovery?. <i>Trends in Microbiology</i> , 2018, 26, 892-895.	3.5	14
290	Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing. <i>PLoS ONE</i> , 2018, 13, e0193432.	1.1	2
291	Contribution of QuantiFERON-TB Gold-in-Tube to the Diagnosis of Mycobacterium tuberculosis Infection in Young Children in a Low TB Prevalence Country. <i>Frontiers in Pediatrics</i> , 2019, 7, 291.	0.9	7
292	Immunology of Mycobacterium tuberculosis Infections. <i>Microbiology Spectrum</i> , 2019, 7, .	1.2	152

#	ARTICLE	IF	CITATIONS
293	Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2019, 39, 1483-1497.	1.5	9
294	Estimates of Testing for Latent Tuberculosis Infection and Cost, United States, 2013. <i>Public Health Reports</i> , 2019, 134, 522-527.	1.3	3
295	<p>Association between vitamin D and latent tuberculosis infection in the United States: NHANES, 2011â€“2012</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 2251-2257.	1.1	13
296	QuantIFERONÂ®-TB Gold In-Tube reliability for immigrants with parasitic infections in Boston, USA. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 482-490.	0.6	5
297	Latent Tuberculosis Infection among Healthcare Workers in Duhok Province: From Screening to Prophylactic Treatment. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 85.	0.9	10
298	Tuberculosis incidence among infected contacts detected through contact tracing of smear-positive patients. <i>PLoS ONE</i> , 2019, 14, e0215322.	1.1	13
299	Latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis on TST and IGRA. <i>Infection</i> , 2019, 47, 353-361.	2.3	23
300	Window Period Prophylaxis for Children Exposed to Tuberculosis, Houston, Texas, USA, 2007â€“2017. <i>Emerging Infectious Diseases</i> , 2019, 25, 523-528.	2.0	6
301	Suspected colonic cancer turns out to be disseminated tuberculosis in a kidney transplant recipient. <i>Medicine (United States)</i> , 2019, 98, e16995.	0.4	4
302	Performance Evaluation of a New Automated Chemiluminescent Immunoanalyzer-Based Interferon-Gamma Releasing Assay AdvanSure I3 in Comparison With the QuantiFERON-TB Gold Inâ€“Tube Assay. <i>Annals of Laboratory Medicine</i> , 2020, 40, 33-39.	1.2	9
303	Positive conversion of interferon-Î³ release assay in patients with rheumatic diseases treated with biologics. <i>Rheumatology International</i> , 2020, 40, 471-479.	1.5	7
304	Factors Associated with Latent Tuberculosis Infection among the Hospital Employees in a Tertiary Hospital of Northeastern Thailand. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6876.	1.2	2
305	Modeling the Impact of Recommendations for Primary Careâ€“Based Screening for Latent Tuberculosis Infection in California. <i>Public Health Reports</i> , 2020, 135, 172S-181S.	1.3	10
306	Effect of pregnancy and HIV infection on detection of latent TB infection by Tuberculin Skin Test and QuantiFERON-TB Gold In-Tube assay among women living in a high TB and HIV burden setting. <i>International Journal of Infectious Diseases</i> , 2020, 101, 235-242.	1.5	8
307	Tuberculosis Infection Screening in 5468 Italian Healthcare Students: Investigation of a Borderline Zone Value for the QFT-Test. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6773.	1.2	1
308	Tuberculosis in Internationally Displaced Children Resettling in Harris County, Texas, USA, 2010â€“2015. <i>Emerging Infectious Diseases</i> , 2020, 26, .	2.0	4
309	Serial testing of health care workers for tuberculosis infection: A prospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0235986.	1.1	4
310	Predictive value of TNF-Î±, IFN-Î³, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. <i>BMC Infectious Diseases</i> , 2020, 20, 553.	1.3	6

#	ARTICLE	IF	CITATIONS
311	Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021, 73, e2278-e2284.	2.9	10
312	Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. <i>Clinical Infectious Diseases</i> , 2020, 73, e3555-e3562.	2.9	9
313	Neurologic infections during pregnancy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2020, 172, 79-104.	1.0	26
314	Detection of tuberculosis in cynomolgus macaques (<i>Macaca fascicularis</i>) using a supplementary Monkey Interferon Gamma Releasing Assay (mIGRA). <i>Scientific Reports</i> , 2020, 10, 16759.	1.6	13
315	Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e1116-e1125.	2.9	27
316	Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study. <i>PLoS ONE</i> , 2020, 15, e0233159.	1.1	4
317	Of tuberculosis and non-tuberculous mycobacterial infections – a comparative analysis of epidemiology, diagnosis and treatment. <i>Journal of Biomedical Science</i> , 2020, 27, 74.	2.6	123
318	Public Health Response to Tuberculosis Outbreak among Persons Experiencing Homelessness, Minneapolis, Minnesota, USA, 2017–2018. <i>Emerging Infectious Diseases</i> , 2020, 26, 420-426.	2.0	18
319	Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. <i>Journal of Infection</i> , 2020, 80, 536-546.	1.7	38
320	Whole Blood Stimulation Assay as a Treatment Outcome Monitoring Tool for VL Patients in Ethiopia: A Pilot Evaluation. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	1
321	Screening for Latent Tuberculosis in Children With Immune-Mediated Inflammatory Diseases Treated With Anti-Tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests. <i>Archives of Rheumatology</i> , 2020, 35, 20-28.	0.3	4
322	Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	25
323	Adults with Mycobacterium tuberculosis infection and pre-diabetes have increased levels of QuantiFERON interferon-gamma responses. <i>Tuberculosis</i> , 2020, 122, 101935.	0.8	7
324	Obesity and Prevalence of Latent Tuberculosis: A Population-Based Survey. <i>Infectious Diseases: Research and Treatment</i> , 2021, 14, 117863372199460.	0.7	1
325	Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110284.	1.1	5
326	Schistosoma mansoni Infection Is Associated With a Higher Probability of Tuberculosis Disease in HIV-Infected Adults in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 157-163.	0.9	6
327	Artificial neural network to predict the effect of obesity on the risk of tuberculosis infection. <i>Journal of Public Health Research</i> , 2021, 10, .	0.5	1
328	Harnessing Big Data to Optimize an Algorithm for Rapid Diagnosis of Pulmonary Tuberculosis in a Real-World Setting. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 650163.	1.8	6

#	ARTICLE	IF	CITATIONS
329	Low-dose steroids are associated with indeterminate QuantiFERON-TB Gold In-Tube assay results in immunocompetent children. <i>Scientific Reports</i> , 2021, 11, 6468.	1.6	9
330	Impact of T-Cell Xtend on T-SPOT. TB Assay in High-Risk Individuals after Delayed Blood Sample Processing. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	1
331	Evaluation of the performance of QuantiFERON®-TB Gold plus test in active tuberculosis patients. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2021, 23, 100223.	0.6	2
332	The TB _{Ag} /PHA ratio in T-SPOT.TB assay has high prospective value in the diagnosis of active tuberculosis: a multicenter study in China. <i>Respiratory Research</i> , 2021, 22, 165.	1.4	5
333	<i>Mycobacterium tuberculosis</i> â€‘derived circulating cell-free DNA in patients with pulmonary tuberculosis and persons with latent tuberculosis infection. <i>PLoS ONE</i> , 2021, 16, e0253879.	1.1	18
334	Mycobacterial lymphadenitis without granuloma formation in a patient with anti-interferon-gamma antibodies. <i>International Journal of Hematology</i> , 2021, 114, 630-635.	0.7	3
335	Association between monocyte-to-lymphocyte ratio and tuberculin skin test positivity in HIV-positive adults. <i>PLoS ONE</i> , 2021, 16, e0253907.	1.1	5
336	Latent tuberculosis infection: Misperceptions among non-U.S.â€‘born-populations from countries where tuberculosis is common. <i>Global Public Health</i> , 2022, 17, 1728-1742.	1.0	3
337	Pulmonary Tuberculosis After Therapy with Anti-Tumor Necrosis Factor (TNF) for Crohn Disease: A Case Report. <i>American Journal of Case Reports</i> , 2021, 22, e932963.	0.3	1
338	TCA cycle remodeling drives proinflammatory signaling in humans with pulmonary tuberculosis. <i>PLoS Pathogens</i> , 2021, 17, e1009941.	2.1	21
339	Elevated Rates of Indeterminate Results on QuantiFERON-TB Gold Plus in COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0141421.	1.8	5
340	Tuberculosis Screening in Silica-Exposed Workers. <i>Public Health Reports</i> , 2021, , 003335492110415.	1.3	0
341	Tryptophan catabolism reflects disease activity in human tuberculosis. <i>JCI Insight</i> , 2020, 5, .	2.3	44
342	Diagnosis of Tuberculosis in an Asymptomatic Child, Sibling, and Symptomatic Pregnant Mother in New York City by Tuberculin Skin Testing and the Importance of Screening High-Risk Urban Populations for Tuberculosis. <i>American Journal of Case Reports</i> , 2018, 19, 1004-1009.	0.3	2
343	T-SPOT.TB in Detection of Active Tuberculosis During Pregnancy: A Retrospective Study in China. <i>Medical Science Monitor</i> , 2016, 22, 57-60.	0.5	6
344	Management of Infants and Children who are Contacts of Contagious Tuberculous Patients = ù...ø¹øšù,,ø-ø© øšù,,ø±ø¹ø¹ ùr øšù. Sultan Qaboos University Medical Journal, 2013, 13, 477-485.	0.3	2
345	Is IP-10 an Accurate Marker for Detecting M. tuberculosis-Specific Response in HIV-Infected Persons?. <i>PLoS ONE</i> , 2010, 5, e12577.	1.1	73
346	Unusual Interferon Gamma Measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube Tests. <i>PLoS ONE</i> , 2011, 6, e20061.	1.1	28

#	ARTICLE	IF	CITATIONS
347	Multiple Cytokines Are Released When Blood from Patients with Tuberculosis Is Stimulated with Mycobacterium tuberculosis Antigens. PLoS ONE, 2011, 6, e26545.	1.1	68
348	Prospective Monitoring Reveals Dynamic Levels of T Cell Immunity to Mycobacterium Tuberculosis in HIV Infected Individuals. PLoS ONE, 2012, 7, e37920.	1.1	7
349	Immune Responses to ESAT-6 and CFP-10 by FASCIA and Multiplex Technology for Diagnosis of M. tuberculosis Infection; IP-10 Is a Promising Marker. PLoS ONE, 2012, 7, e43438.	1.1	43
350	In Vitro Immunomodulation of a Whole Blood IFN- γ Release Assay Enhances T Cell Responses in Subjects with Latent Tuberculosis Infection. PLoS ONE, 2012, 7, e48027.	1.1	10
351	Repeat IGRA Testing in Canadian Health Workers: Conversions or Unexplained Variability?. PLoS ONE, 2013, 8, e54748.	1.1	63
352	Strategy to Better Select HIV-Infected Individuals for Latent TB Treatment in BCG-Vaccinated Population. PLoS ONE, 2013, 8, e73069.	1.1	15
353	Variability of the QuantiFERON [®] -TB Gold In-Tube Test Using Automated and Manual Methods. PLoS ONE, 2014, 9, e86721.	1.1	15
354	Tuberculin Skin Testing and Treatment Modulates Interferon-Gamma Release Assay Results for Latent Tuberculosis in Migrants. PLoS ONE, 2014, 9, e97366.	1.1	23
355	Vulnerability of Homeless People in Tehran, Iran, to HIV, Tuberculosis and Viral Hepatitis. PLoS ONE, 2014, 9, e98742.	1.1	26
356	Comparison of the Tuberculin Skin Test and Interferon Gamma Release Assay for the Screening of Tuberculosis in Adolescents in Close Contact with Tuberculosis TB Patients. PLoS ONE, 2014, 9, e100267.	1.1	14
357	Quantiferon-TB Gold: Performance for Ruling out Active Tuberculosis in HIV-Infected Adults with High CD4 Count in CÔte d'Ivoire, West Africa. PLoS ONE, 2014, 9, e107245.	1.1	7
358	The Prevalence and Incidence of Latent Tuberculosis Infection and Its Associated Factors among Village Doctors in China. PLoS ONE, 2015, 10, e0124097.	1.1	36
359	Neutrophil-to-Lymphocyte Ratio Is Associated with Impaired Interferon-Gamma Release to Phytohemagglutinin. PLoS ONE, 2015, 10, e0125794.	1.1	14
360	Cough Aerosol Cultures of Mycobacterium tuberculosis: Insights on TST / IGRA Discordance and Transmission Dynamics. PLoS ONE, 2015, 10, e0138358.	1.1	16
361	Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012. PLoS ONE, 2015, 10, e0140881.	1.1	134
362	High Latent TB Infection Rate and Associated Risk Factors in the Eastern China of Low TB Incidence. PLoS ONE, 2015, 10, e0141511.	1.1	48
363	Abrupt Decline in Tuberculosis among Foreign-Born Persons in the United States. PLoS ONE, 2016, 11, e0147353.	1.1	19
364	Yield of community-based tuberculosis targeted testing and treatment in foreign-born populations in the United States: A systematic review. PLoS ONE, 2017, 12, e0180707.	1.1	10

#	ARTICLE	IF	CITATIONS
365	A borderline range for Quantiferon Gold In-Tube results. PLoS ONE, 2017, 12, e0187313.	1.1	48
366	Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis. PLoS ONE, 2017, 12, e0188631.	1.1	63
367	Enduring Challenge of Latent Tuberculosis in Older Nursing Home Residents: A Brief Review. Journal of Clinical Medicine Research, 2019, 11, 385-390.	0.6	5
368	Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and Public Health Practice. Morbidity and Mortality Weekly Report, 2019, 68, 552-553.	9.0	7
369	Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association. MMWR Recommendations and Reports, 2020, 69, 1-27.	26.7	34
370	Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection. Pathogens and Immunity, 2016, 1, 291.	1.4	18
371	Clinical Application of Interferon- γ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence. Pathogens and Immunity, 2016, 1, 308.	1.4	16
372	The Challenging Evaluation of Patients with Severe Psoriasis for Latent Tuberculosis: An Important Indication for IGRA. Open Respiratory Medicine Journal, 2011, 5, 59-60.	1.3	5
373	Serial IGRA testing of trainees in the healthcare sector in a country with low incidence for tuberculosis - a prospective cohort study. GMS Hygiene and Infection Control, 2013, 8, Doc17.	0.2	14
374	Usefulness of interferon- γ release assay for the diagnosis of latent tuberculosis infection in young children. Korean Journal of Pediatrics, 2016, 59, 256.	1.9	11
375	Tuberculosis Transmission in a Primary School and a Private Language School. An Estimation of Infectivity. Frontiers in Pediatrics, 2020, 8, 10.	0.9	5
376	Clinical characteristics and the usefulness of the QuantiFERON-TB Gold In-Tube test in hematologic patients with hepatic or splenic lesions. Korean Journal of Internal Medicine, 2013, 28, 187.	0.7	7
377	Qualitative and quantitative results of interferon- γ release assays for monitoring the response to anti-tuberculosis treatment. Korean Journal of Internal Medicine, 2017, 32, 302-308.	0.7	10
378	The Infectivity of Pulmonary Tuberculosis in Korean Army Units: Evidence from Outbreak Investigations. Tuberculosis and Respiratory Diseases, 2019, 82, 298.	0.7	5
379	Comparison of interferon gamma release assay & tuberculin skin tests for diagnosis of latent tuberculosis in patients on maintenance haemodialysis. Indian Journal of Medical Research, 2015, 141, 463.	0.4	10
380	Insight into the diagnosis and management of subclinical genital tuberculosis in women with infertility. Journal of Human Reproductive Sciences, 2016, 9, 135.	0.4	18
381	Comparison of QuantiFERON-TB gold in tube test versus tuberculin skin test for screening of latent tuberculosis infection in Saudi Arabia: A population-based study. Annals of Thoracic Medicine, 2016, 11, 197.	0.7	3
382	Orofacial tuberculosis: Clinical manifestations, diagnosis and management. Journal of Family Medicine and Primary Care, 2015, 4, 335.	0.3	19

#	ARTICLE	IF	CITATIONS
383	Comparison of tuberculin skin test and QuantiFERON-TB Gold In-Tube test in Bacillus Calmette-Guérin-vaccinated children. <i>Lung India</i> , 2020, 37, 24.	0.3	6
384	Comparison of the tuberculin skin test and the QuantiFERON-TB Gold test in detecting latent tuberculosis in health care workers in Iran. <i>Epidemiology and Health</i> , 2016, 38, e2016032.	0.8	9
385	Risk Factors for False-Negative Interferon- γ Release Assay Results in Culture-Confirmed Childhood TB. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 1303-1307.	0.6	9
386	Overweight, Obesity, and Older Age Favor Latent Tuberculosis Infection among Household Contacts in Low Tuberculosis-Incidence Settings within Panama. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1141-1144.	0.6	11
387	Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?. <i>Turkish Journal of Gastroenterology</i> , 2019, 29, 292-298.	0.4	5
388	Curving Tuberculosis: Current Trends and Future Needs. <i>Annals of Global Health</i> , 2019, 85, .	0.8	12
389	Retrospective Study of Measuring Tuberculosis Therapy Compliance: Greece as a Host Country for Vulnerable Populations Before and During the Financial Crisis. <i>Materia Socio-medica</i> , 2015, 27, 325.	0.3	3
390	Agreement between the results of tuberculin skin test and Interferon-Gamma Release Assays in renal transplant candidates. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 88.	0.4	1
391	COVID-19 and Beyond: Exploring Public Health Benefits from Non-Specific Effects of BCG Vaccination. <i>Microorganisms</i> , 2021, 9, 2120.	1.6	5
392	Clinical Trial: Magnetoplasmonic ELISA for Urine-based Active Tuberculosis Detection and Anti-Tuberculosis Therapy Monitoring. <i>ACS Central Science</i> , 2021, 7, 1898-1907.	5.3	16
393	The use of Quantiferon-TB gold in-tube test in screening latent tuberculosis among Saudi Arabia dialysis patients. <i>Annals of Thoracic Medicine</i> , 2015, 10, 284-8.	0.7	5
394	Toward a generation free of tuberculosis: TB disease and infection in individuals of college age in the United States. <i>Journal of American College Health</i> , 2018, 66, 17-22.	0.8	3
395	Biologics in Juvenile Idiopathic Arthritis-Main Advantages and Major Challenges: A Narrative Review. <i>Archives of Rheumatology</i> , 2021, 36, 146-157.	0.3	9
396	T-spot [®] .TB test for latent tuberculosis infection diagnosis and treatment guidance in Thai health-care professionals. <i>Indian Journal of Occupational and Environmental Medicine</i> , 2020, 24, 47.	0.6	0
397	Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country. <i>Drugs in Context</i> , 2020, 9, 1-7.	1.0	3
399	Geographic analysis of latent tuberculosis screening: A health system approach. <i>PLoS ONE</i> , 2020, 15, e0242055.	1.1	1
400	The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 179-84, i-iii.	0.6	25
401	Risk-based immunization policies and tuberculosis screening practices for animal care and research workers in the United States: survey results and recommendations. <i>Journal of the American Association for Laboratory Animal Science</i> , 2012, 51, 561-73.	0.6	3

#	ARTICLE	IF	CITATIONS
402	Molecular Characterization of Environmental Non-Tuberculous Mycobacteria Using PCR- RFLP Analysis of 441 Bp Heat Shock Protein 65 Fragments. Iranian Journal of Public Health, 2012, 41, 108-14.	0.3	12
403	Tuberculosis and the obstetrician-gynecologist: a global perspective. Reviews in Obstetrics and Gynecology, 2013, 6, 174-81.	0.7	4
404	ROLES OF PUBLIC HEALTH CENTERS () IN TUBERCULOSIS CONTROL IN JAPAN. Nagoya Journal of Medical Science, 2015, 77, 19-28.	0.6	17
405	Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis - Colorado, 2011-2012. Morbidity and Mortality Weekly Report, 2013, 62, 805-9.	9.0	6
406	Extent and effects of recurrent shortages of purified-protein derivative tuberculin skin test antigen solutions - United States, 2013. Morbidity and Mortality Weekly Report, 2013, 62, 1014-5.	9.0	5
407	National shortage of purified-protein derivative tuberculin products. Morbidity and Mortality Weekly Report, 2013, 62, 312.	9.0	8
408	Insights in Public Health: Eliminating Tuberculosis in Hawai'i: Yesterday, Today, and Tomorrow. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2016, 75, 117-20.	0.4	0
409	IFN- γ and IL-2 Responses to Recombinant AlaDH against ESAT-6/CFP-10 Fusion Antigens in the Diagnosis of Latent versus Active Tuberculosis Infection. Iranian Journal of Medical Sciences, 2017, 42, 275-283.	0.3	6
410	Performance of 4 methods for screening of latent tuberculosis infection in patients with chronic inflammatory arthritis under TNF α inhibitors: a 24-month prospective study. Advances in Rheumatology, 2021, 61, 71.	0.8	3
411	Biomarkers to identify <i>Mycobacterium tuberculosis</i> infection among borderline QuantiFERON results. European Respiratory Journal, 2022, 60, 2102665.	3.1	11
412	US Postarrival Evaluation of Immigrant and Refugee Children with Latent Tuberculosis Infection Diagnosed Overseas, 2007-2019. Journal of Pediatrics, 2022, 245, 149-157.e1.	0.9	3
413	Tuberculosis in Children. Infectious Disease Clinics of North America, 2022, 36, 49-71.	1.9	16
416	Overseas Treatment of Latent Tuberculosis Infection in US "Bound Immigrants. Emerging Infectious Diseases, 2022, 28, 582-590.	2.0	5
417	The Biological and Clinical Aspects of a Latent Tuberculosis Infection. Tropical Medicine and Infectious Disease, 2022, 7, 48.	0.9	10
419	Risk of latent tuberculosis infection among healthcare workers in Italy: a retrospective study with Quantiferon Test.. Journal of Preventive Medicine and Hygiene, 2021, 62, E759-E762.	0.9	0
420	Treatment in Latent Tuberculosis Uveitis "Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory?. Journal of Clinical Medicine, 2022, 11, 2419.	1.0	3
421	Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?. Rheumatology International, 2022, 42, 1797-1806.	1.5	0
422	A data driven policy to minimise the tuberculosis testing cost among healthcare workers. International Journal of Health Planning and Management, 2022, , .	0.7	1